Abstract-Traditional drug discovery practice usually follows the "one drug -one target" approach, seeking to identify drug molecules that act on individual targets, which ignores the systemic nature of human diseases. Pathway-based drug discovery recently emerged as an appealing approach to overcome this limitation. An important first step of such pathway-based drug discovery is to identify associations between drug molecules and biological pathways. This task has been made feasible by the accumulating data from high-throughput transcription and drug sensitivity profiling. In this paper, we developed "iPaD", an integrative Penalized Matrix Decomposition method to identify drug-pathway associations through jointly modeling of such high-throughput transcription and drug sensitivity data. A scalable bi-convex optimization algorithm was implemented and gave iPaD tremendous advantage in computational efficiency over current state-of-the-art method, which allows it to handle the ever-growing large-scale data sets that current method cannot afford to. On two widely used real data sets, iPaD also significantly outperformed the current method in terms of the number of validated drug-pathway associations that were identified. The Matlab code of our algorithm publicly available at http://licong-jason. github.io/iPaD/
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INTRODUCTION
I DENTIFICATION of potential therapeutic drug molecules for a disease of interest, which is known as "drug-discovery", is a critical step in new drug development. Traditional drug discovery practice in the pharmaceutical industry usually follows the "one drug -one target" approach, which seeks to identify drugs that act on individual molecules that are involved in the pathological process [1] . However, this approach ignores the systemic nature of human diseases and may account for a significant increase in the attrition rate of new candidate drugs due to low efficacy and serious side effects [2] , [3] . Specifically, the pathological process of a disease usually involves extremely complex interplays between many functionally related biological molecules within certain disease-related pathways [4] . Targeting a single component in a disease-related pathway may not provide sufficient interference to the whole pathological process, which may result in unsatisfactory therapeutic efficacy. Moreover, it does not allow researchers to investigate the effects of drug molecules at a systems level, limiting its utility in evaluating drug safety and toxicity in early drug development stages [5] .
Pathway-based drug discovery recently emerged as an appealing approach to overcome the limitations of the one drug -one target approach [6] , [7] , [8] . Instead of focusing on the interference of drug molecules on individual targets, pathway-based analysis seeks to understand the effect of a drug molecule on a whole biological pathway. The knowledge about the effects of drug molecules upon the diseaserelated pathways would allow researchers to identify more effective candidate drugs. However, currently not much is known about the complex relationships between drug molecules and biological pathways, and an important first step is to infer associations between them before delving into their complex relationships.
High-throughput transcription and drug sensitivity profiles have become routine products of pharmacogenomics studies [9] , [10] , [11] . For example, the NCI-60 project [12] , [13] performed whole genome transcription profiling of 60 cancer cell lines and measured their sensitivities to several thousands of drug molecules. Assuming the transcription and drug sensitivity levels are both associated with the activity levels of certain biological pathways, joint modeling of these two types of data could provide valuable information regarding the pathway activities, drug-pathway and gene-pathway relationships. With this mindset, [14] proposed an integrative statistical framework named "iFad", which is built on a Bayesian sparse factor analysis model, to infer drug-pathway associations by jointly analyzing the gene expression data and drug sensitivity data. They applied their method to the NCI-60 gene expression and drug sensitivity data set and identified significant drug associations for eight types of cancers separately. Despite its satisfactory power in identifying drug-pathway associations, iFad performs statistical inferences using Markov Chain Monte Carlo (MCMC), which is very computationally expensive. Moreover, its results might be sensitive to several prior parameters that need to be specified by the users.
Besides the NCI-60 project, a more recent effort to characterize the transcription and drug sensitivity profiles of various cancer cell lines is the Cancer Cell Line Encyclopedia (CCLE) project [15] . Compared with the NCI-60 data set, a noteworthy feature of the CCLE data set is its large sample size -more than 400 cancer cell lines have been profiled for their transcription levels and drug sensitivities. Analyzing such a large data set using iFad would incur very huge computational cost. In fact, in [14] , iFad was only used to analyze each cancer type separately (each cancer type has only 6$9 samples). Analyzing all the cell lines together would cost tens to hundreds of hours depending on the number of MCMC iterations. Apparently, the ever-increasing data sizes of paired transcription and drug sensitivity data sets present an pressing need for more computationally efficient methods for drug-pathway association analysis. In this article, we introduce "iPaD", an integrative Penalized Matrix Decomposition method for drug-pathway association analysis. Compared with iFad, our method has two unique features: 1) the association analysis is formulated into a bi-convex optimization problem which can be solved with a very efficient algorithm and hence greatly reduces the computational cost compared to the MCMC algorithm in iFad; 2) our method is almost tuning-free -the only tuning parameter can be easily determined through cross-validation. We demonstrated the practical utility of our method on two relatively large real data sets, the pooled NCI-60 data set with all eight types of cancers and the CCLE data set. We also compared power to detect drug-pathway associations between iPaD and iFad through comprehensive simulations. We organize the rest of this article as follows. We explain the iPaD model and its optimization algorithms in the next section, followed by real data applications and results for simulation studies. We summarize the conclusions in the final section.
METHODS
Model Description
Consider N samples (usually cell lines) with both transcription and drug sensitivity profiles available. Let Y ð1Þ 2 R NÂG ð1Þ
and Y ð2Þ 2 R NÂG ð2Þ denote the transcription and drug sensitivity profiles respectively, where G ð1Þ is the number of genes that are measured and G ð2Þ is the number of drug molecules that are assayed. We consider the activity levels of biological pathways as a set of common latent factors that underly the gene expression and drug sensitivity profiles. The activity levels of K pathways for the N cell lines are denoted as a matrix X 2 R NÂK and we use B ð1Þ and B ð2Þ to denote the loading matrices for pathway-gene associations and pathway-drug associations. Then the gene expression and drug sensitivity profiles are modeled as follows: 
where jj Á jj 1 stands for the ' 1 norm, i.e., jjAjj 1 ¼ P i P j jA ij j. This ' 1 norm penalty is an effective and popular device to achieve sparse solutions in high-dimensional regression which was first introduced in the so-called "lasso" (least absolute shrinkage and selection operator) regression [16] , which attempts to solve a high-dimensional regression problem while applying an ' 1 norm constraint on its solution. With such a constraint, some coefficients in the solution may be shrunk to exact zeros. The constraint on B ð1Þ is used to incorporate known gene-pathway relationships. The constraint on the columns of X ensures the identifiability of the model.
Optimization Algorithm
We note that problem (2) is a bi-convex optimization problem, i.e., when X is fixed, optimizing B ð1Þ and B ð2Þ are both convex problems and when B ð1Þ and B ð2Þ are fixed, optimizing X is also a convex problem. This property naturally motivates the following alternating optimization algorithm (Algorithm).
Next, we describe the optimization algorithm for X, B
and B ð2Þ separately.
Optimizing X
The optimization problem for X can be rewritten as follows:
where Y ¼ ½Y ð1Þ Y ð2Þ and B ¼ ½B ð1Þ B ð2Þ . We used an iterative projected gradient descent algorithm to solve this problem. Specifically, at each iteration, the gradient of the objective function is calculated and we let X take a step along the negative direction of the gradient and projected it to the feasible region: fX :
We use the Nesterov's method to accelerate its convergence [17] . In Nesterov's method, after each gradient descent iteration, the solution is moved further in the direction and step size given by the the last two steps, achieving a convergence rate of order 1=t 2 instead of order 1=t of the ordinary gradient descent method. 
We use the readily available and very efficient coordinate descent algorithm to solve each lasso problem [18] , [19] .
We note that this setup does not allow incorporating known drug-pathway associations. When such prior knowledge is available and needs to be incorporated, we modify problem (5) is the indicator matrix representing the known drug-pathway associations similarly to L ð1Þ .
Handling Missing Values
In this section, we describe how missing values in the transcription data and drug sensitivity data are dealt with in iPaD. As mentioned earlier, when optimizing B ð1Þ and B ð2Þ , each column of these two matrices can be solved separately. Therefore, missing values can be simply removed from each column of Y ð1Þ and Y ð2Þ while solving each column of B
and B ð2Þ . Optimizing X is not straightforward because it needs to be solved as a whole matrix. Suppose that the observed values in Y are indexed by V 2 f0; 1g
NÂðG ð1Þ þG ð2Þ Þ . We define an operator P V that projects matrix X onto the linear space supported by V,
Then when Y ð1Þ or Y ð2Þ contains missing values, the optimization problem for X can be written as:
Define V ? ¼ 1 À V as the index matrix for the missing values in Y and rewrite the objective function in problem (7):
This simple observation motivates the following iterative algorithm to solve problem (7), in which the estimate of X at each iteration is then plugged into P V ? ðXBÞ for optimizing (8) in the next iteration (Algorithm 2). This is essentially the spirit of the soft-impute algorithm from the incomplete matrix learning problem [20] .
Repeat steps 1 and 2 until convergence.
We prove that Algorithm 2 indeed gives the global optimal solution for problem (7) in the Supplementary Materials, which can be found on the Computer Society Digital Library at http://doi.ieeecomputersociety.org/10.1109/ TCBB.2015.2462344.
Parameter Tuning and Significance Test
In our method, is a critical parameter that controls the sparsity of the drug-pathway association matrix, B ð2Þ . Similar to many other penalized methods such as lasso, one way to assess the relative importance of the coefficients in B ð2Þ is to solve the problem for a decreasing sequence of values and record the order of the coefficients in which they became non-zero-the more important coefficients are supposed to become non-zeros earlier than the less important ones. However, this procedure does not allow evaluation of the significance of the coefficients. Alternatively, we can first find an appropriate value of and then perform permutation test to assess the significance of the coefficients.
We use ten-fold cross-validation to find an appropriate value. Specifically, the Y ð2Þ matrix is evenly partitioned into n folds as illustrated in Fig. 1 . In each round of cross-validation, each of the ten folds is masked as missing values while the other entries are treated as observed values. Then we solve the iPaD problem for a sequence of values. The residual sum of squares (RSS) of the masked values for the ten folds are evaluated for each . The that gives the smallest RSS is chosen. Given the value, the significance of the coefficients in B ð2Þ can be assessed via permutation test. In each permutation, the rows in Y ð2Þ are shuffled whereas Y ð1Þ is kept unchanged. After the estimates of the B ð2Þ in the permuted data sets are obtained, the p-value of each coefficient in the B ð2Þ matrix is calculated as follows,
i;j j ! jB ð2Þ i;j jÞ T ;
where T is the total number of permutations,B ð2ÞðtÞ is the B ð2Þ estimate in the tth permutation andB ð2Þ is the B ð2Þ estimate in the original data.
RESULTS AND DISCUSSION
Real Data Applications
We applied iPaD to analyze the same NCI-60 data set that was analyzed in [14] . The detailed data pre-processing procedure can be found in their paper. The processed data set consists of 57 cell lines from eight different cancer types with gene expression levels of 1,863 genes covering 58 KEGG pathways [21] and drug sensitivity profiles for 101 chemical compounds/drugs as measured by GI 50 values, which is a commonly used measure for drug potency and is defined as the concentration required for 50 percent of maximum cell growth inhibition. The gene-pathway association matrix L ð1Þ has a density of 3:95 percent whereas the drugpathway association prior knowledge matrix L ð2Þ has a density of 0:51 percent. [14] advocated analyzing the eight types of cancer cell lines separately by demonstrating the heterogeneity among the inferred drug-pathway association patterns across different cancer types. Therefore, we first used our method to analyze the eight types of cancer separately. However, we did not find much consistency between our results and the results reported in [14] (results not shown). A possible explanation is that the very limited sample size (only 6$9 cell lines per cancer type) for each cancer type probably could not provide reliable statistical inference. Then we pooled the data for the eight cancer types and analyzed them using both iFad and iPaD. For iFad, we ran 10,000 iterations with the first 7,000 iterations discarded as burn-in. MCMC samples were recorded every tenth iteration. Both h 0 and h 1 parameters were set to zero for genepathway associations. h 1 was set to zero and h 0 was set at 0.05 for drug-pathway associations. As for iPaD, we first used ten-fold cross-validation to choose the value and then performed 10,000 permutations to evaluate the significance levels of the identified associations. For the purpose of comparison, we also analyzed the data set with a gene set enrichment analysis (GSEA) method. Specifically, for each drug, we tested for its association with each gene using a simple linear regression and ranked the genes according to their significance levels of association. Then we performed a Kolmogorov-Smirnov test for the enrichment of significant genes in each pathway.
Due to the stochastic nature of the MCMC algorithm in iFad, we repeated the analysis for five times. On average, 123 drug-pathway pairs had posterior probabilities greater than or equal to 0.9. Among them, 25.2 associations were validated in the CancerResource database [22] , which was also used in [14] to validate their inferred drug-pathway associations. Whereas for iPaD, although the optimization algorithm itself is deterministic, the permutation test is stochastic. Therefore we also ran iPaD for five times. On average, 277.2 associations had p-values less than or equal to 0.05, with 81 validated in the CancerResource database. If we set the p-value cutoff at 0.005, 59.4 associations were identified, with 20.2 associations validated in the CancerResource database. Among the top 100 associations identified by GSEA, 23 were validated. Apparently, the drug-pathway pairs identified by iPaD are more enriched for validated associations than those identified by the other two methods. To better compare the results from these two methods, we performed the following analysis. First, the list of all drugpathway pairs were ranked based on their significance in both iFad, iPaD and GSEA results. Then we slid a bin that consists of 20 consecutive drug-pathway pairs from the top to the bottom of the list. For example, the first bin consists of the 20 most significant drug-pathway pairs and the next bin starts from the second most significant drug-pathway pair and runs through the 21st most significant pair, and so on. Then the number of validated drug-pathway pairs in each bin was counted. The results averaged for the five runs for the first 100 bins were shown in Fig. 2a . Clearly, among the top drug-pathway pairs identified by the three methods, Tables S1-S5 and S6-S10 for iFad and iPaD respectively. We also list the top 100 drug-pathway associations identified through GSEA in Table S11 .
We also applied both iFad and iPaD to the data set from the CCLE project. This data set contains 480 cancer cell lines with transcription profiles for 18,988 genes and drug sensitivities profiles for 24 chemical compounds/drugs. The drug sensitivities were measured by EC 50 , IC 50 , maximum activity ('A max ') and area over the dose-response curve ('activity area'). Like GI 50 , both EC 50 and IC 50 are commonly used measures of drug potency. 'A max ', instead, is a measure of drug efficacy. In this paper, we chose the 'activity area' as our measure for drug sensitivity due to two considerations: 1) it simultaneously captures both drug potency and efficacy; 2) it had much fewer missing values than the other measures in the CCLE data set. We took logtransformation of both the transcription and drug sensitivity profile data before further analysis. Because this is also a cancer-specific data set, the genes in the CCLE data set were intersected with the 1,863 genes used in [14] and only 1,802 genes were left. The same 58 KEGG pathways used in [14] were also used in our analysis. The CCLE data set also provided the known targets of each of the 24 drugs. However, the target genes of two drugs were not annotated in any KEGG pathways and thus we were excluded them from our analysis. For the remaining 22 drugs, a pathway is defined as the target of a drug if any member of the pathway is a target of the drug. The known drug-pathway associations were not used as prior knowledge but as post-analysis validations. Because the CCLE data set is relatively large, running 10,000 iterations for iFad is infeasible in practice. Therefore we ran only 2,000 iterations, with the first 1,000 iterations discarded as burn-in. Correspondingly, only 2,000 permutations were performed in the iPaD analysis. However, the estimated p-values are of limited resolutions with only 2,000 permutations. To overcome this limitation, we estimated the p-values by approximating the null distribution of each coefficient as a mixture of a point mass at zero and a normal distribution.
Again, the analysis was repeated five times for iPaD and iFad. Moreover, we also analyzed the CCLE data set using the GSEA approach described earlier. On average, iFad identified 39.4 drug-pathway pairs that had posterior probabilities no smaller than 0.9, with 4.8 of them being validated associations. Whereas for iPaD, 82 drug-pathway pairs had p-values no greater than 0.05 and 23 pairs were among the validated associations. Again, iPaD outperformed iFad in identifying the validated associations. As for GSEA results, among the top 100 associations, only 1 was validated. As a more comprehensive comparison of the results of the iFad and iPaD, we also performed similar analysis as we did on the NCI-60 results. The enrichment curves for the first 100 bins for the two methods are shown in Fig. 2b . The top 10 associations identified by iPaD were listed in Table 1 . In the iPaD results, two EGFR inhibitors, Erlotinib and Lapatinib are associated with the ErbB signaling pathway. It is well known that EGFR is a key component of the ErbB signaling pathway and the latter plays a key role in the regulation of cell proliferation, migration, differentiation, apoptosis. Mis-regulations of these activities are hallmarks most cancer cells. In addition, two Raf kinase inhibitors, Sorafenib and PLX4720 are associated with the Chronic myeloid leukemia pathway. In the Chronic myeloid leukemia pathway, Raf kinase is a critical player that regulates the MAPK signaling pathway and hence controls cell proliferation. We also note that Panobinostat, a histone deacetylase (HDAC) inhibitor, was found to be associated with the regulation of actin cytoskeleton pathway. Although HDAC and cytoskeleton are seemingly unrelated, we found that a study published in 2012 [23] suggested that Panobinostat could also induce hyperacetylation of tublin, a major component of the microtubule cytoskeleton, and affects microtubule dynamics and organization. As for the iFad results, there was not much consistency between the top associations from the five repeats. The identified drugpathway pairs for each run are listed in Tables S12-S16 and S17-S21 for iFad and iPaD, respectively. We also list the top 100 drug-pathway associations identified through GSEA in Table S22 .
We note that although pooling together data from different cancer types allows us to increase the sample size and better identify the pan-cancer common signals, it may also dilute the signals that are specific to certain cancer types. Therefore we also performed an analysis on the lung cancer cell lines of the CCLE data set. We chose lung cancer between it has the largest sample size (N ¼ 91) among all the cancer types. Similarly, iFad, iPaD and GSEA were separately used to analyze this data set. Similar to previous results, iPaD achieved the highest enrichment for validated associations, followed by iFad, and then GSEA. The enrichment curves for the three methods are shown in Fig. 2c . The 15 associations with p-values smaller than 0.01 in iPaD were listed in Table 2 . Similar to previous results, EGFR inhibitors such as Lapatinib and Erlotinib continue to appear in validated association. In addition, multi-kinase inhibitor Sorafenib was found to be associated with the Focal adhesion pathway. Focal adhesions are sub-cellular structures that link cells to the extracellular matrix. Several studies have already reported the up-regulation or activation of focal adhesion kinases in human lung cancer cells [24] , [25] . In the focal adhesion pathway, the focal adhesion kinase is regulated by several target kinases of Sorafenib such as KDR, FLT4, PDGFRB and so on. A more comprehensive list of the identified associations on this lung cancer data set is in the supplementary materials (Table S23-S33) , available online.
The permutation test allows us to evaluate the significance of the identified drug-pathway associations at the expense of substantially increased computational cost. However, we note that such cost is still much more affordable than the MCMC in iFad. For example, on the NCI-60 data set, 10,000 MCMC iterations cost around 230 hours for iFad. Whereas for iPaD, even with 10,000 permutations, it took only about 30 hours. For the CCLE data set, 2,000 MCMC iterations cost about 150 hours. Yet it took only 6 hours on average to run 2,000 permutations with iPaD. All the computation times in this article were estimated on a standard laptop computer (2.4 GHz dual core CPU with 4 G memory running the Mac OS X 10.9 operating system). In addition, if the permutation test is still not affordable, iPaD could offer an alternative way to evaluate the relative importance of the identified associations without performing the costly permutation test. When a decreasing sequence of values are solved, the order in which the drug-pathway association coefficients become non-zero can be used as indications of their relative importances, i.e., the coefficients that becomes non-zeros at larger values can be considered as more important. In the real data applications, we also plotted the enrichment curve obtained through this procedure in Fig. 2 (denoted as 'iPaD_seq'). Compared with their rankings of p-values, the drug-pathway pairs may be ranked differently using this procedure. But it is noteworthy that it still achieved better overall enrichment for validated associations than iFad on the two real data sets. Moreover, the computational cost was further greatly reduced-it took only about 15 and 30 minutes to obtain the rankings of the first 50 percent of the drug-pathway pairs for the NCI-60 data set and the CCLE data set, respectively.
Simulation Studies
We first generated a pathway activity level matrix X 2 R NÂK with each entry simulated from a standard normal distribution independently. To better mimic real applications, we generated an indicator matrix L ð1Þ 2 f0; 1g
by randomly choosing K pathways from the 58 KEGG pathways used in the previous section, where G ð1Þ is the number of unique genes that are involved in any of the K pathways. Given a pre-defined h value that controls the sparsity of B ð2Þ ,
we generated another indicator matrix L 
is zero (this will happen when a drug has no target pathway), we use the sample variance of all the entries in the non-zero columns as its variance and simulate its entries from a mean-zero normal distribution.
After the simulation data were generated, we used both iPaD and iFad to analyze the data and measured their performances by the AUC (area under the receiver operating characteristic curve). For both methods, the gene-pathway relationships in L ð1Þ matrix was treated as prior knowledge whereas L ð2Þ was treated as unknown. For iPaD, we solved a decreasing sequence of values until 70 percent of the coefficients in B ð2Þ were non-zero and compared the order in which the coefficients in B ð2Þ became non-zero against their true association status in L ð2Þ to obtain the receiver operating characteristic (ROC) curve and then calculated the area under this curve (AUC). For iFad, both h 0 and h 1 parameters were set to zero for gene-pathway associations so that their association statuses were fixed during the MCMC iterations. The h 1 parameter was set to 0 for drugpathway associations so that the known associations were never "turned off" whereas the h 0 for drug-pathway associations were set to 0:1 to allow novel associations to be inferred. The default values were used for the other parameters. The total number of MCMC iterations was set to 500 (burn-in ¼ 250). MCMC samples were recorded every tenth iteration. The AUCs for iFad were calculated by comparing the association posterior probabilities for the drug-pathway pairs and their true association statuses. We only ran 500 iterations for two reasons: 1) the AUC almost plateaued at 500 iterations; 2) the computational cost is too high. Because the performance of iFad also depends on the number of MCMC iterations, we also evaluated its performance with 10 and 50 iterations. For the purpose of comparison, we also analyzed the simulated data set with GSEA.
The performances in terms of AUC and comprehensive time cost profiles of three methods are shown in Tables 3  and 4 (the time cost for GSEA is not shown because its AUC is not competitive). We let the sample size N ¼ 480, the number of drugs G ð2Þ ¼ 22, the number of pathways K ¼ 58, h ¼ 0:1, and varied the SNR from 0.1 to 1. We also evaluated the effect of sample size by fixing SNR ¼ 0:5 and varied N from 120 to 480. As expected, the AUC increases as the sample size and SNR increase. We also simulated data with unequal SNRs for transcription levels and drug sensitivities and with different h values. The AUCs of iFad and iPaD are always similar to each other regardless of the sample size and SNR when we run enough number of iterations for iFad. Both methods substantially outperformed GSEA. Although the performances of the two methods were similar, iPaD cost much less time than iFad. For example, when N ¼ 480, it took about 5 minutes to run iPaD on the simulated data set. Whereas 500 MCMC iterations would cost more than one day for iFad. Even only 10 iterations would cost as much as half an hour for iFad.
We note that although the two methods had similar performances on the simulated data sets, iPaD surprisingly achieved higher enrichment for validated associations in the real data applications. One possible explanation is that the MCMC algorithm in iFad did not converge with the number of MCMC iterations used in our analyses. However, further increasing the number of iterations will make the computation time even more unaffordable in practice. Another explanation is that the default prior parameters of iFad might not The first five columns are the simulation settings. The last four columns are the time costs in minutes. Note that iFad10, iFad50, and iFad500 denote iFad with 10, 50 and 500 iterations respectively.
be appropriate for the real data sets in our analyses. If this is the case, the results might indicate that iFad is not very robust with respect to the choice of its prior parameters in practice. It could also be explained by the potential difference between the simulation settings and the unknown nature of the real data sets. Finally, it might also be the case that the known drug-pathway associations are not 100 percent complete and accurate. We admit that these associations are probably not complete, which may limit the interpretability of the results to some extent. But we think their accuracy should be relatively reliable since the drug targets are either well established in the literature or carefully curated in the specific databases by experts. Therefore we argue that our results still provide compelling evidence that iPaD performs better than iFad on the two real data sets.
CONCLUSIONS
Various high-throughput experiment data have become increasingly available to facilitate drug target identification, which have also posed a major challenge for effectively integrating these different types of data. We have developed a method called iPaD, which is based on penalized matrix decomposition, to jointly analyze transcription and drug sensitivity data to identify drug-pathway associations. Thanks to its scalable bi-convex optimization algorithm, iPaD has tremendous advantage in computational efficiency over the existing state-of-the-art method called iFad, which has been demonstrated through both simulation studies and real data applications. Another notable advantage of iPaD is that only one parameter needs to be tuned and we have derived an efficient cross-validation procedure to tune this parameter. Yet iFad has quite a few prior parameters that need to be specified by users. In terms of the accuracy of the identified associations, iFad and iPaD had similar performances on simulated data sets. In real data applications, iPaD seemed to outperform iFad, although the assessment might be complicated by the completeness and accuracy of the known associations that were used for validation. We also note for the two data sets we analyzed, the compounds in the CCLE data set are better characterized than those in the NCI-60 data set in general. Therefore the known associations are more reliable for the CCLE data set and interpretation of its results is easier than that of the NCI-60 data set. Therefore in the real data analysis, we focused on the interpretation of the results from the CCLE data set. We note that statistical inference/test is notoriously difficult for problems with lasso-type penalty and therefore we had to use a permutation test to evaluate the significance levels of the identified associations. Although the permutation test substantially increased the computational cost, iPaD still takes much less time than iFad in the real data applications. In addition, compared with MCMC, permutation is more amenable to parallel computing, and therefore the computation time of iPaD can be further reduced if the permutation procedure was parallelized. Moreover, as demonstrated in both simulation studies and real data applications, a much more computationally affordable and still useful way to evaluate the relative importance the identified drug-pathway association is to rank them based on the order in which their coefficients become non-zeros. Indeed, this strategy cannot provide rigorous statistical inference as in iFad. But it should be kept in mind that the posterior probabilities provided by iFad need to be interpreted with caution as they can be affected by the several pre-specified prior parameters, especially the prior probability of each drug-pathway association coefficient being non-zero.
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